-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EG-501 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-501 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EG-501 in Systemic Lupus Erythematosus Drug Details:EG-501 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-017 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-017 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EG-017 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-001 in Idiopathic Interstitial Pneumonia (IIP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-001 in Idiopathic Interstitial Pneumonia (IIP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EG-001 in Idiopathic Interstitial Pneumonia (IIP)Drug Details:EG-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Irinotecan Hydrochloride in Pancreatic Ductal Adenocarcinoma Drug Details: Irinotecan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Itacitinib Adipate in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Itacitinib Adipate in Non-Hodgkin Lymphoma Drug Details: Itacitinib adipate (INCB-39110)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Relapsed Multiple Myeloma Drug Details: Abemaciclib (Verzenio / Verzenios...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Endometrial Cancer Drug Details: Trametinib (GSK1120212,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trametinib Dimethyl Sulfoxide in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trametinib Dimethyl Sulfoxide in Bile Duct Cancer (Cholangiocarcinoma)...
-
Sector Analysis
Ethylene Glycol Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Ethylene Glycol Industry Capacity & CapEx Overview The Ethylene Glycol industry capacity was 60.06 million tonnes per annum (mtpa) in 2023 and it is expected to increase at an AAGR of more than 5% during 2023-2028. Around 40 planned and announced plants are slated to come online by 2028, primarily in Asia and the Middle East. This will boost the market growth during the forecast years. Ethylene Glycol Industry Capacity and CapEx Outlook, 2023-2028 (mtpa) Buy the Full Report for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dapirolizumab Pegol in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapirolizumab Pegol in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapirolizumab Pegol in Systemic Lupus Erythematosus Drug Details: Dapirolizumab pegol...